We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+1.76%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.4B
AUM Growth
+$1.5B
Cap. Flow
+$1.66B
Cap. Flow %
7.75%
Top 10 Hldgs %
50.4%
Holding
201
New
31
Increased
27
Reduced
32
Closed
37

Top Buys

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$1.41B
2
CHTR icon
Charter Communications
CHTR
+$462M
3
CBRE icon
CBRE Group
CBRE
+$375M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$314M
5
VMW
VMware, Inc
VMW
+$285M

Top Sells

Rank Stock Value
1
EFX icon
Equifax
EFX
+$249M
2
IQV icon
IQVIA
IQV
+$239M
3
BIIB icon
Biogen
BIIB
+$172M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$130M
5
TMO icon
Thermo Fisher Scientific
TMO
+$105M

Sector Composition

Rank Sector Weight
1 Healthcare 31.13%
2 Technology 23.99%
3 Financials 9.09%
4 Communication Services 6.05%
5 Industrials 4.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FBRX icon
101
Forte Biosciences
FBRX
$1.63B
$1.2M 0.01%
+72,418
New +$1.61M
OKLO
102
Oklo
OKLO
$7.83B
$1.02M ﹤0.01%
98,300
– –
SAGE
103
DELISTED
Sage Therapeutics
SAGE
$881K ﹤0.01%
+42,800
New +$1.24M
SMC
104
Summit Midstream
SMC
$470M
$806K ﹤0.01%
58,214
– –
EDU icon
105
New Oriental
EDU
$8.88B
$761K ﹤0.01%
13,000
– –
CYTK icon
106
Cytokinetics
CYTK
$10.7B
$641K ﹤0.01%
21,772
– –
LU icon
107
Lufax Holding
LU
$1.2B
$636K ﹤0.01%
150,000
-4,837,455
-97% -$26.8M
MDGL icon
108
Madrigal Pharmaceuticals
MDGL
$11.9B
$485K ﹤0.01%
3,319
– –
GRND.WS
109
DELISTED
Grindr Inc. Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
GRND.WS
$427K ﹤0.01%
540,000
– –
BNTX icon
110
BioNTech
BNTX
$29.3B
$418K ﹤0.01%
3,844
– –
KRTX
111
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$372K ﹤0.01%
2,200
– –
ALNY icon
112
Alnylam Pharmaceuticals
ALNY
$31.6B
$354K ﹤0.01%
2,000
– –
LUNRW
113
DELISTED
Intuitive Machines, Inc. Warrants
LUNRW
$265K ﹤0.01%
950,000
– –
HIMS icon
114
Hims & Hers Health
HIMS
$7.88B
$264K ﹤0.01%
+42,000
New +$312K
KRYS icon
115
Krystal Biotech
KRYS
$10.3B
$232K ﹤0.01%
+2,000
New +$244K
CHE icon
116
Chemed
CHE
$7.07B
$208K ﹤0.01%
+400
New +$208K
HQY icon
117
HealthEquity
HQY
$8.81B
$205K ﹤0.01%
+2,800
New +$189K
AKRO
118
DELISTED
Akero Therapeutics
AKRO
$202K ﹤0.01%
+4,000
New +$186K
EHC icon
119
Encompass Health
EHC
$11.9B
$201K ﹤0.01%
3,000
-97,000
-97% -$6.67M
BPMC
120
DELISTED
Blueprint Medicines
BPMC
$201K ﹤0.01%
4,000
-18,420
-82% -$984K
FOLD
121
DELISTED
Amicus Therapeutics
FOLD
$195K ﹤0.01%
+16,000
New +$206K
RCM
122
DELISTED
R1 RCM Inc. Common Stock
RCM
$181K ﹤0.01%
12,000
-540,000
-98% -$9.08M
COGT icon
123
Cogent Biosciences
COGT
$6.37B
$166K ﹤0.01%
17,000
-966,452
-98% -$11.5M
AAC.WS
124
DELISTED
Ares Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
AAC.WS
$137K ﹤0.01%
200,000
– –
SEDA.WS
125
DELISTED
SDCL EDGE Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary share at an exercise price of $11.50
SEDA.WS
$108K ﹤0.01%
866,250
– –
3 4
5
6 7

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2023 Portfolio in Review

As of Q3 2023, Thomas Steyer held 201 positions worth $21.4B, up 7.5% from $19.9B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Thomas Steyer deployed $1.66B of net new capital in Q3 2023, opening 31 new positions and adding to 27 existing holdings. Its largest new stake was Charter Communications: 1,111,341 shares worth $489M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 35% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was IQVIA, an estimated $239M trimmed.

  • Thomas Steyer's largest Q3 2023 buy was Charter Communications: 1,111,341 shares worth $489M.
  • Thomas Steyer added most to Activision Blizzard in Q3 2023, an estimated $1.41B increase.
  • Thomas Steyer's biggest Q3 2023 reduction was IQVIA, cutting an estimated $239M.
  • Thomas Steyer fully exited Equifax in Q3 2023, selling an estimated $249M.
  • Thomas Steyer's ten largest holdings make up 50% of its $21.4B portfolio in Q3 2023.
  • Thomas Steyer opened 31 new positions and closed 37 in Q3 2023.
  • Thomas Steyer's portfolio value rose 7.5% quarter-over-quarter to $21.4B.

Based on Farallon Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.